EMAIL THIS PAGE TO A FRIEND

Urological research

Naftopidil and tolterodine in the medical expulsive therapy for intramural ureteral stones: a prospective randomized study.


PMID 22926289

Abstract

We performed a randomized, prospective study to assess the possible role of combined naftopidil and tolterodine for facilitating the spontaneous expulsion of intramural ureteral stones. A total of 76 patients with intramural ureter stones were included in the study from December 2007 to February 2011. Patients were randomized to one of three treatment groups. Group A patients received naftopidil 25xa0mg/day, group B patients received naftopidil 25xa0mg/day plus tolterodine 2xa0mg (twice a day), and group C patients received tolterodine 2xa0mg (twice a day). Both groups were followed up for 2xa0weeks. The stone expulsion rate and time and the number of pain episodes were obtained. Subjects rated the urgency associated with each micturition using the Urinary Sensation Scale (USS). Pain descriptions were recorded by the patients using the visual analog scale (VAS). A significant difference was shown for the expulsion rate between the group C and the other two groups (Pxa0

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

N158
Naftopidil hydrochloride hydrate, solid
C24H28N2O3 · xHCl · yH2O
PZ0009
Tolterodine L-tartrate, ≥98% (HPLC)
C22H31NO·C4H6O6